



**ASX ANNOUNCEMENT**

**21 November 2019**

**Company Announcements Office  
ASX Limited  
Exchange Centre  
20 Bridge Street  
SYDNEY NSW 2000**

Dear Sir / Madam,

**Notification under sections 708A(5)(e) of the Corporations Act 2001 (Cth)**

CardieX has issued an Appendix 3B with respect to the conversion of 640,303 Notes held by C2 Ventures Pty Ltd into 21,343,425 ordinary shares of the Company.

Details of the issue of shares are set out in the announcement of 21 November 2019 and in the Appendix 3B lodged on the same day.

CardieX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

1. Under the issue, CardieX has issued 21,343,425 ordinary shares at the issue price of \$0.03 per share, raising approximately \$640,303 without disclosure to investors under Part 6D.2 of the Corporations Act;
2. As at the date of this notice:
  - (a) CardieX has complied with the provisions of Chapter 2M of the Act;
  - (b) CardieX has complied with section 674 of the Act; and
  - (c) there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act.

Yours faithfully,

A handwritten signature in blue ink, appearing to read "Jarrod White", with a large, stylized flourish at the end.

**Jarrod White**  
**Company Secretary | Chief Financial Officer**  
Chief Financial Officer  
Jarrod White

[jwhite@cardiex.com](mailto:jwhite@cardiex.com)

**Investor Relations**  
**Peter Taylor – NWR Communications**

[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)

**About CardieX**

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" (cBP) which is considered essential for the management of hypertension and related cardiovascular disorders. XCEL was developed and is marketed by CardieX's 100% subsidiary, ATCOR.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September 2019, the Company signed an agreement with Mobvoi, Google's partner in China, for the co-development of new wearable technologies and devices based on Mobvoi's smart watch products.